GX-19
GX-19| 백신설명 | |
|---|---|
| 대상 | 사스-코브-2 |
| 백신종류 | DNA |
| 임상자료 | |
| 기타 이름 | GX-19N |
| 경로: 행정 | 근육내 |
| 식별자 | |
| 드러그뱅크 | |
| 다음 시리즈의 일부 |
| COVID-19 전염병 |
|---|
 |
|
.svg){kind=small} COVID-19 포털 |
GX-19는 제넥신 컨소시엄이 개발한 COVID-19 백신 후보물질이다.[1][2][3][4]
사스-CoV-2 스파이크 단백질을 암호화하는 DNA 기반 백신이다.[5]
참조
- ^ "Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults". ClinicalTrials.gov. United States National Library of Medicine. 24 June 2020. NCT04445389. Archived from the original on 11 October 2020. Retrieved 14 July 2020.
- ^ "Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults". clinicaltrials.gov. United States National Library of Medicine. 18 January 2021. Retrieved 16 March 2021.
{{cite journal}}: CS1 maint : url-status (링크) - ^ "S. Korea's Genexine begins human trial of coronavirus vaccine". Reuters. 19 June 2020. Archived from the original on 11 October 2020. Retrieved 25 June 2020.
- ^ "Genexine consortium's Covid-19 vaccine acquires approval for clinical trails in Korea". 11 June 2020. Retrieved 1 August 2020.
- ^ Seo YB, Suh YS, Ryu JI, Jang H, Oh H, Koo BS, et al. (March 2021). "Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates". Vaccines. 9 (4): 307. doi:10.3390/vaccines9040307. PMC 8063950. PMID 33804981.
 | 스콜리아는 GX-19 (Q106616276)에 대한 프로필을 가지고 있다. |
.png){kind=small}
